Biotechnology

A 'dream team' of pharma veterans has raised $180M to advance a next-gen oral drug, promising to transform the multi-billion dollar IBD market.

As CFO Dave Denton departs for the consumer goods sector, Pfizer taps a 20-year veteran for the interim role, signaling continuity amid a crucial post-acquisition phase.

Merck secures a pivotal FDA approval for its CAPVAXIVE vaccine, offering new hope for at-risk youth and challenging rivals in the high-stakes pneumococcal market.

A Taipei delegation at BIO 2026 signals Taiwan's strategic pivot from manufacturing to R&D, seeking global partners for its late-stage drugs and platforms.

A half-million dollar grant is just the start. A new public-private alliance is mobilizing to fight blast-induced brain injuries. Here's the story behind the numbers.

At BIO 2026, Transpire Bio isn't just presenting; it's pitching a new paradigm for medicine, using inhalation to tackle everything from diabetes to cancer.

Early trial data for a novel antibody-drug conjugate shows a 32% response rate in a hard-to-treat patient group, signaling a potential new front in precision oncology.

German biotech Mallia Aesthetics reports impressive results for its hormone-free hair serum, but the real story lies in its resilient, science-first strategy.

After three decades, a new class of therapy for a rare liver disease lands in Singapore, rewriting the rules of care by targeting patient suffering, not just lab results.

Iceland's Alvotech secured a crucial capital infusion. It's a high-stakes play to survive financial pressures and compete in the next wave of affordable medicine.

A new report projects the wellness market will hit $12.9T by 2031. This isn't just about yoga mats; it's a tech-fueled, Asia-led economic realignment.

As Oncoinvent accelerates its Phase 2 trial, a novel alpha-emitter therapy shows promise against a deadly cancer, signaling progress in radiopharmaceuticals.

After a 20-year drought, positive Phase 3 data for oral olorofim signals a safer, potent new option against a deadly fungus, promising a major market shake-up.

An AMWC 2026 award for RRS® HA Long Lasting signals a market shift. How Skin Tech Pharma Group is creating a new category beyond fillers and boosters.

An Arkansas lab's $30 million settlement with the DOJ offers a rare look into 'lean lab' models and the fine line between business and patient care.

GSK and Spero Therapeutics have won FDA approval for Utebzi, the first oral carbapenem for complex UTIs, a move that could slash healthcare costs.

Kilroy Realty’s major debt restructuring isn't just a financial footnote; it's a strategic masterclass in navigating market turmoil and unlocking future growth.

A partnership between Chef Carla Hall and The Fresh Market shows how retail fundraising directly enables cutting-edge diagnostics and treatments in the fight against Alzheimer's.

Healthcare firm Cosmos Health is diversifying into the crowded skincare market with a DTC brand. Can its science-first approach disrupt the beauty industry?

A Florida hospital just rebuilt a baby's heart in stages. It's not just a medical first; it's a new blueprint for innovation where execution trumps hype.